Centene Corporation Reports Strong Earnings and Positive Outlook
Money

Centene Corporation Reports Strong Earnings and Positive Outlook

authorBy T. Harv Eker
DateAug 04, 2026
Read Time3 min

Hotchkis & Wiley, an investment management firm, recently issued its second-quarter 2026 investor correspondence for its "Mid-Cap Value Fund." The letter highlighted robust equity market performance during the quarter, with the Russell Midcap Index climbing 13.8% and the Russell Midcap Value Index increasing by 13.4%. These gains occurred despite ongoing concerns about inflation, a hawkish Federal Reserve stance, and rising oil prices stemming from geopolitical tensions. The market saw concentrated leadership, particularly from semiconductor and AI-related stocks, which often delivered returns exceeding 100%. Hotchkis & Wiley prioritizes high-quality businesses with attractive valuations, downplaying exaggerated fears surrounding AI's impact. The Mid-Cap Value Fund, however, trailed the Russell Midcap Value Index, achieving a 4.74% return, mainly due to underperformance in the technology and energy sectors, though healthcare selections provided positive contributions.

A key factor in the Mid-Cap Value Fund's positive results for the second quarter of 2026 was the strong performance of Centene Corporation (NYSE:CNC). Centene is a healthcare company based in the U.S., providing services to underinsured and uninsured families, as well as commercial organizations. As of August 3, 2026, Centene's stock closed at $63.76 per share, giving it a market capitalization of $31.49 billion. Over the preceding 52 weeks, Centene's shares saw an impressive gain of 146.27%. The company is recognized for its focus on the Medicaid market, serving approximately 28 million at-risk enrollees and holding one of the largest Medicaid market shares among publicly traded entities. Its business model, characterized by low capital intensity, positions it to benefit from the ongoing shift in U.S. healthcare towards government-funded, cost-controlled initiatives. Centene's exceptional performance in this quarter was driven by adjusted earnings per share that surpassed consensus estimates by 48%, a boosted full-year outlook from management, and increased investor confidence in the recovery of Medicaid margins and the effective reset of Affordable Care Act (ACA) memberships.

Centene Corporation, while delivering strong results, is not featured on our list of the most sought-after stocks among hedge funds entering 2026. Although we recognize its investment potential, we believe that certain AI-focused companies may offer superior growth opportunities with reduced risk. For those seeking an undervalued AI stock poised to benefit from current trade policies and domestic manufacturing trends, a detailed report on the top short-term AI stock is available.

Centene's success highlights the potential for companies to thrive even in complex economic environments, particularly when they effectively adapt to market demands and optimize operational efficiencies. This demonstrates the importance of strategic positioning and responsive management in achieving financial growth and investor confidence, offering a compelling example of resilience and foresight in the healthcare sector.

More Articles
Money
Elevance Health's Financial Rebound Anticipated in 2027
Greenskeeper Asset Management's Q2 2026 report highlights Elevance Health (ELV) as a significant contributor to their portfolio's performance. Despite a challenging period with elevated medical costs, ELV's profitability is expected to recover, driven by stabilized cost trends and favorable government reimbursement updates. The firm anticipates 2027 will mark a strong earnings recovery, building on ELV's robust commercial health insurance foundation.
By Natalie PaceAug 04, 2026
Money
Argenx SE Expands Vyvgart's Reach in Autoimmune Disease Treatment
Baron Capital's Q2 2026 investor letter highlights Argenx SE's progress with Vyvgart, an FcRn inhibitor. The company aims to demonstrate its efficacy across a wider spectrum of autoimmune conditions, showing promise in clinical trials and maintaining a strong pipeline. This development comes despite leadership changes, reinforcing investor confidence in its future growth.
By Vicki RobinAug 04, 2026
Money
The Enduring Principle of Long-Term Investment Success
This article explores the core principle shared by the most successful investors throughout history: eschewing market timing in favor of a consistent, long-term approach. Drawing on historical data and expert analysis, it demonstrates the inherent difficulty and low probability of consistently profiting from short-term market fluctuations, highlighting how staying invested, even through volatile periods, ultimately leads to greater wealth accumulation.
By JL CollinsAug 04, 2026
Money
Olin Corp. Poised for Recovery Amidst Chlor-alkali Market Shift
Olin Corporation (OLN) is expected to see a stock recovery driven by a tightening chlor-alkali market, despite recent underperformance. A Q2 2026 investor letter from Hotchkis & Wiley Mid-Cap Value Fund highlights the company's strong position as a major producer of chlor-alkali chemicals, anticipating increased demand and pricing. The company's strategic merger with Huntsman and commitment to a strong balance sheet further support its potential for growth.
By Dave RamseyAug 04, 2026
Money
AI Integration Boosts Alphabet's Core Business
Greenskeeper Asset Management's Q2 2026 report highlights Alphabet (GOOG) as a top performer. The company's AI integration has dispelled fears of cannibalization, with Search revenue growing nearly 20% and Cloud division backlog doubling. This success demonstrates AI's role in enhancing Alphabet's core value and solidifying its market leadership in search, cloud, digital advertising, and AI.
By Vicki RobinAug 04, 2026